Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578


Delayed Quote. Delayed  - 10/27 05:35:09 pm
68.86 EUR   +1.10%
10/27 SANOFI : Pasteur, Fiocruz, and WRAIR Agree to Collaborate on Zika Va..
10/25 SANOFI : - Sanofi : signs landmark agreement to combat antimicrobial..
10/25 GLOBAL DIABETIC : Nono Nordisk, Eli Llly, Sanofi, Merk, Tonghua Dong..
News SummaryMost relevantAll newsSector news 

SANOFI : EMA Recommends Approval Of Sanofi Pediatric Vaccine Hexyon/Hexacima 6-in-1

share with twitter share with LinkedIn share with facebook
share via e-mail
02/22/2013 | 01:58pm CEST

PARIS--The Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) recommended market approval for Sanofi Pasteur's 6-in-1 pediatric vaccine, French drugs giant Sanofi (>> SANOFI) said Friday.


- Hexyon/Hexacima is the only fully liquid, ready-to-use, 6-in-1 vaccine to protect infants against diphtheria, tetanus, pertussis (whooping cough), Hepatitis B, poliomyelitis and invasive infections caused by Haemophilus influenzae type b.

- The new vaccine will be commercialized under the brand name Hexyon in Western European countries by Sanofi Pasteur MSD, the joint venture between MSD and Sanofi Pasteur, and under the brand name Hexacima in Eastern European countries by Sanofi Pasteur.

- The vaccine "reduces the number of vaccination visits for infants and it is more convenient for parents to complete the recommended vaccination schedule and thus better protect their children against six major childhood diseases," said Olivier Charmeil, President and CEO of Sanofi Pasteur.

-Hexyon/Hexacima would be indicated for primary and booster vaccination of infants from six weeks of age in accordance with official recommendations.

- The CHMP positive opinion is supported by results of multi-center clinical studies involving approximately 5,000 infants; phase III clinical studies comparing Hexyon/Hexacima to licensed combination vaccines demonstrated that HexyonTM/HexacimaTM is safe and induces a robust immune response against all six targeted diseases.

-Write to Mimosa Spencer at mimosa.spencer@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : SANOFI
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on SANOFI
10/27 SANOFI : Science 37 Secures $31M Series B Funding to Expand Clinical Trial Acces..
10/27 SANOFI : Pasteur, Fiocruz, and WRAIR Agree to Collaborate on Zika Vaccine Resear..
10/25 SANOFI : - Sanofi : signs landmark agreement to combat antimicrobial resistance
10/25 GLOBAL DIABETIC NEPHROPATHY (INSULIN : Nono Nordisk, Eli Llly, Sanofi, Merk, Ton..
10/25SANOFI SA : quaterly earnings release
10/21 SANOFI : Genzyme Assigned Patent
10/19 PROMIS NEUROSCIENCES : announces appointment of Dr. Richard Gregory to its Board..
10/18 GLOBAL MENINGOCOCCAL INFECTIONS VACC : Sanofi-Pasteur, Beijing Tiantan Biologica..
10/18 SCHNEIDER ELECTRIC : Three air france apprentices win prizes at altern'up
10/13 REGENERON PHARMACEUTICALS : and Sanofi Announce Positive Dupixent® dupilumab Pha..
More news
Sector news : Pharmaceuticals - NEC
10/27DJPFIZER : Files 8K - Changes Executive Management
10/27 ASTRAZENECA : pauses two cancer drug trials' enrolment due to bleeding
10/27DJBRISTOL MYERS SQUIBB : Makes Moves to Reassure Investors
10/27DJBRISTOL MYERS SQUIBB : Makes Moves to Reassure Investors
10/27DJApple Unveils Macs With Touch-Screen Keyboard
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
10/27 Biogen Flat For 3 Years While EPS Rise 150%; Is It A Buy Yet?
10/27 Notable earnings before Friday?s open
10/27 WALL STREET BREAKFAST : Semiconductor Consolidation Continues
10/27 Sanofi accelerates Zika vaccine work
10/18 In Less Than A Month, Regeneron's Luck Kicks In
Financials (€)
Sales 2016 36 665 M
EBIT 2016 9 178 M
Net income 2016 5 260 M
Debt 2016 5 715 M
Yield 2016 4,39%
P/E ratio 2016 15,37
P/E ratio 2017 14,17
EV / Sales 2016 2,55x
EV / Sales 2017 2,57x
Capitalization 87 802 M
More Financials
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus HOLD
Number of Analysts 25
Average target price 81,3 €
Spread / Average Target 19%
Consensus details
EPS Revisions
More Estimates Revisions
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & EVP-Finance
Elias E. Zerhouni President-Global Research & Development
Yong-Jun Liu Head-Global Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI-13.35%95 774
JOHNSON & JOHNSON11.53%313 422
ROCHE HOLDING LTD.-17.44%196 913
PFIZER INC.0.37%196 527
NOVARTIS AG-16.42%188 199
MERCK & CO., INC.15.24%168 318
More Results